Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Receivables (2023 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Receivables for 3 consecutive years, with $25.3 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 169.45% to $25.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.3 million through Dec 2025, up 169.45% year-over-year, with the annual reading at $25.3 million for FY2025, 169.45% up from the prior year.
  • Receivables hit $25.3 million in Q4 2025 for ARS Pharmaceuticals, down from $40.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $40.7 million in Q3 2025 to a low of $652000.0 in Q4 2023.
  • Historically, Receivables has averaged $16.4 million across 3 years, with a median of $10.3 million in 2025.
  • Biggest YoY gain for Receivables was 4302.16% in 2025; the steepest drop was 169.45% in 2025.
  • Year by year, Receivables stood at $652000.0 in 2023, then surged by 1342.79% to $9.4 million in 2024, then soared by 169.45% to $25.3 million in 2025.
  • Business Quant data shows Receivables for SPRY at $25.3 million in Q4 2025, $40.7 million in Q3 2025, and $27.2 million in Q2 2025.